FOURTH RESEARCH WORKSHOP ON HEAD AND NECK CANCER

第四届红斑狼疮生物学与防治研究研讨会 头颈部癌症打算成为一个多学科的国际组织 研究论坛，强调所有相关领域的新研究进展 头颈癌。主要目标是刺激增加 基础科学研究人员和专职临床医生之间的互动。 我们还试图让这两个群体接触到目前的国家癌症研究所 优先事项。国际研究人员在两个项目中的参与 基础和临床科学一直受到大力鼓励 国际协调员的参与。 第四次研究研讨会第一次组织会议召开 1992年7月28日，在加利福尼亚州旧金山(见所附会议纪要 出席情况和本次会议的总结)。一项决定是保留 会议策划人。尊敬的We Plan Meetings，Inc.总裁Ruth Enquist女士， 是一位经验丰富的策划者。弗吉尼亚州的阿灵顿被选为选址 因为它接近美国大学的研究和管理人才 美国国家癌症研究所。如会议纪要所示，计划涉及 大量忠诚的临床医生(来自内科肿瘤学、放射科) 肿瘤学和外科)和科学家从一开始。确实是 普遍认为，广泛拥有这次会议的所有权将导致 比过去更多的参与。 要强调的主题包括：流行病学；致癌；预防； 细胞生物学；免疫学；遗传学；新的治疗策略；前 临床治疗.临床试验更新.质量 生活/康复。主题将以全体会议的形式介绍。 会议、主旨演讲、提供的论文和海报。

The 4th Research Workshop on the Biology, Prevention, and Treatment of Head and Neck Cancer is intended to be a multi-disciplinary international research forum stressing new research developments in all fields related to head and neck cancer. The prime objective is to stimulate increased interaction between basic science researchers and committed clinicians. We also seek to expose both groups to current National Cancer Institute priorities. Participation from international researchers in both the basic and clinical sciences has been strongly encouraged through the involvement of international coordinators. The initial organizational meeting for the 4th Research Workshop was held on July 28, 1992, in San Francisco, California (see attached minutes for attendance and a summary of this meeting). A decision was made to retain a meeting planner. Ms. Ruth Enquist, President of We Plan Meetings, Inc., is an experienced planner. Arlington, Virginia was selected as the site because of proximity to the research and administrative talent of the National Cancer Institute. As indicated in the minutes, plans involved a large number of committed clinicians (from medical oncology, radiation oncology, and surgery) and scientists from the beginning. It was generally felt that wide ownership of this meeting would lead to even greater participation than in the past. Topics to be emphasized include: Epidemiology; Carcinogenesis; Prevention; Cell Biology; Immunology; Genetics; Novel Therapeutic Strategies; Pre- Clinical Therapies; Clinical Trial Updates; Quality of Life/Rehabilitation. Topics will be presented in the form of plenary sessions, keynote addresses, proffered papers and posters.